The US Food and Drug Administration has approved a drug by Zydus Cadila used to treat dementia of the Alzheimer's type, the Indian pharmaceutical company said on Wednesday.
"We have received the final approval from the USFDA to market Memantine Hydrochloride tablets USP, 5 mg and 10 mg, used for the treatment of moderate to severe dementia of the Alzheimer's type," said the city-based drug major in a regulatory filing on the BSE.
The drug will be produced at the company's formulations manufacturing facility at Moraiya in the city.
"We have 120 regulatory approvals and filed for 300 ANDAs (Abbreviated New Drug Application) for licensed medication since the filing process began in 2003-04," added the filing.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)